• Exosome Proved a Rebel in Dengue Invasion

    As the heat rises in the summer, so does the threat of Dengue fever outbreak. Despite of intensive re-search, there is no effective pharmaceutical treatments for Dengue fever. Personal protection measure to avoid mosquito bites and environmental management to prevent mosquito breeding remain the only avail-able strategies to prevent transmission. In the latest Nature Communications, Dr. Edmond Hsieh’s re-search team ... Read More
  • 2019 Genomic Epidemiology Workshop

    The “2019 Genomic Epidemiology Workshop” organized by Genomics Research Center and Taiwan Epidemiology Association will be held on August 5-9th , 2019. The main courses include study design and analysis of Genome-wide association study (GWAS), Next-generation sequencing (NGS), and Epigenetics. In addition to theoretical classes, the workshop provides practical exercise as well. We sincerely invite you to join us. Read More
  • 14th Asia Epigenome Meeting (AEM) / 3rd Taipei Epigenetics and Chromatin Meeting (TECM)/Abcam Epigenetics Conference

    Time: October 16-18, 2019. Venue: International Conference Hall, Humanities and Social Sciences Building, Academics Sinica. Organizer: Academia Sinica, Abcam. Website and online registration: https://pse.is/GLMHV. Early-bird Registration Deadline: Sunday, June 30, 2019. Contact: Mr. Ming-Lun Kang, +886-2-2789-8775, This email address is being protected from spambots. You need JavaScript enabled to view it. Read More
  • Glycans Promising To Fix Damaged Spinal Axons

    An accident caused the spinal injury, and a person was sentenced to life time on wheels - such traumatic stories are not new, and all those paralyzed are still waiting for new medical breakthroughs. That is why one of the toughest remaining mysteries in life science that make scientists pondering upon eagerly is Neuro-regeneration... Read More
  • For the sake of your pancreas, “Sugarless” please!

    Following the report of an antibody IL-17RB which proved to ease the metastasis of pancreatic cancer back in 2015, Dr. Wen-Hwa Lee’s group made another breakthrough in the study regarding pancreatic ductal adenocarcinoma (PDAC), which is a ferocious kind of pancreatic cancer. In the latest Cell Metabolism journal, the group pinpointed the cause and effect of pancreatic cancer... Read More
  • 1
  • 2
  • 3
  • 4
  • 5

Research in GRC Series


  • The First Prize, National Senior High School Science Fair. Congratulations to Chen-Wei Su and Jou-Wei Ho from Taipei First Girl
    Read More
  • Congratulations to Dr. Tien-Hsien Chang for receiving the Y.Z. HSU SCIENCE AWARD
    Read More
  • Congratulations to Dr. Chun-Mei Hu for receiving the Juei-Low Sung foundation Distinguished Thesis Award
    Read More
  • Congratulations to Dr. Yun-Ru Chen for receiving the 2019 China Youth Corps award
    Read More

Research News

  • All
  • PopularScience
  • ResearchNews
  • Sugar intake in foods / Dr. Wen-Bin Yang
    Read More
    • PopularScience
  • CRISPR: God’s Scissors / Dr. Yu-Chi Chou
    Read More
    • PopularScience
  • Hierachical and Programmable One-Pot Method Brings Oligosaccharide Synthesis to a Whole New Level
    Read More
    • ResearchNews
  • Making the right tools for tough jobs – how to build a scientific instrument / Dr. Yi-Sheng Wang
    Read More
    • PopularScience
  • Glycans Promising To Fix Damaged Spinal Axons
    Read More
    • ResearchNews
  • Circulating Cancer Detection Tool Validated Clustering Key to Metastasis of Head & Neck Cancers
    Read More
    • ResearchNews
load more hold SHIFT key to load all load all

Chang, Tse Wen

ChangTW_6x7.jpgDistinguished Visiting Chair

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-27871252




  • B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972
  • Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977
  • Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980
  • Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981
  • Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985
  • Professor of Molecular Virology, Baylor College of Medicine, 1986-1991
  • Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston
  • Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University
  • President, Development Center for Biotechnology, Taipei, 2000-2003
  • Distinguished Research Fellow, Genomics Research Center, Academia Sinica, 2006-2015
  • Distinguished Visiting Chair, Genomics Research Center, Academia Sinica, 2016-present


  • Foundation for the Advancement of Outstanding Scholarship Award, 1997-2002
  • Appointed Science and Technology Advisor of the Executive Yuan, 2002-2006
  • Xolair (Chang's anti-IgE invention) approved by FDA, USA, 2003
  • Appointed Tsing Hua Professor of Life Science, 2003-2006
  • "Honorary Fellow Award" from American College of Allergy, Asthma, and Immunology (ACAAI), 2004
  • Nature Biotechnology's shortlist of personalities who made the most significant contribution to biotech in the past 10 years. Nature Biotechnology 24, 291-300, 2006
  • Xolair chosen for Prix Galien Award for outstanding innovation in R&D, UK, 2006
  • "Honorary Fellow Award" from American Academy of Allergy, Asthma, and Immunology (AAAAI), 2007
  • "Father of Xolair" plaque from Novartis, in Middle East Asthma and Allergy Conference, Dubai, 2012
  • "Lifetime Achievement Award in Allergy" from Taiwan Academy of Pediatric Allergy, Asthma and Clinical Immunology, 2013
  • TWAS(The World Academy of Sciences) Prize in Medical Sciences, 2014


New drug discovery and antibody engineering

The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.



  • Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, “The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.”, The Journal of allergy and clinical immunology, 135(2), 337-342.e2. (SCI)
  • Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, “Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations.”, Nature communications, 5, 3139. (SCI)
  • Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW, 2010, “Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.”, Journal of immunology, 184(4), 1748-1756. (SCI)
  • Chang TW & Pan AY, 2008, “Cumulative environmental changes, skewed antigen exposure, and the increase of allergy.”, Advances in immunology, 98, 39-83. (SCI)
  • Chang TW, Wu PC, Hsu CL, Hung AF, 2007, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.”, Advances in immunology, 93, 63-119. (SCI)
  • Chang TW & Shiung YY, 2006, “Anti-IgE as a mast cell-stabilizing therapeutic agent.”, The Journal of allergy and clinical immunology, 117(6), 1203-1212. (SCI)
  • Chang TW, 2000, “The pharmacological basis of anti-IgE therapy.”, Nature biotechnology, 18(2), 157-162. (SCI)